← Back to Screener
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Price$3.46
Value ScoreA
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-3.31%
Price vs S&P 500 (4W)-24.57%
VGM Score66.36
Market Capitalization$587.67M
P/E Ratio (Annual)24.47x
All Metrics
P/CF (Annual)4.63x
Book Value / Share (Quarterly)$4.55
P/TBV (Annual)2.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-10.32%
Cash Flow / Share (Quarterly)$0.68
Price vs S&P 500 (YTD)-5.00%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)28.26%
EPS (TTM)$0.58
10-Day Avg Trading Volume2.50M
EPS Excl Extra (TTM)$0.58
Revenue Growth (5Y)-5.33%
EPS (Annual)$0.15
ROI (Annual)16.69%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-9.53%
Cash / Share (Quarterly)$1.34
P/E Basic Excl Extra (TTM)5.75x
Revenue Growth QoQ (YoY)158.87%
EPS Growth (5Y)-25.92%
P/E Normalized (Annual)24.47x
ROA (Last FY)6.05%
Revenue Growth TTM (YoY)13.80%
EBITD / Share (TTM)$1.26
ROE (5Y Avg)-206.33%
Operating Margin (TTM)55.37%
Cash Flow / Share (Annual)$0.78
P/B Ratio0.83x
P/B Ratio (Quarterly)2.31x
Net Income / Employee (Annual)$240,200
EV / Revenue (TTM)2.63x
Net Interest Coverage (TTM)3.44x
ROA (TTM)26.02%
EPS Growth QoQ (YoY)889.04%
EV / EBITDA (TTM)4.71x
EPS Incl Extra (Annual)$0.15
Current Ratio (Annual)1.13x
Quick Ratio (Quarterly)1.38x
3-Month Avg Trading Volume2.75M
52-Week Price Return466.67%
EV / Free Cash Flow (Annual)7.50x
P/E Incl Extra (TTM)5.75x
Revenue / Employee (TTM)$3,615,100
Tangible BV / Share (Quarterly)$-2.10
P/S Ratio (Annual)1.98x
Asset Turnover (Annual)0.75x
52-Week High$5.78
Operating Margin (5Y Avg)-7.34%
EPS Excl Extra (Annual)$0.15
CapEx CAGR (5Y)-54.79%
26-Week Price Return12.62%
Quick Ratio (Annual)1.08x
13-Week Price Return-2.46%
Total Debt / Equity (Annual)0.61x
Current Ratio (Quarterly)1.41x
Enterprise Value$952.05M
Revenue / Share Growth (5Y)-5.60%
Asset Turnover (TTM)0.92x
Book Value / Share Growth (5Y)44.86%
Revenue / Employee (Annual)$2,961,500
Inventory Turnover (Annual)79.67x
Pretax Margin (Annual)23.65%
Cash / Share (Annual)$1.32
3-Month Return Std Dev81.42%
Gross Margin (5Y Avg)96.84%
Net Income / Employee (TTM)$1,021,800
EBITDA CAGR (5Y)-7.28%
EBITDA Interim CAGR (5Y)9.78%
ROE (Last FY)26.83%
Net Interest Coverage (Annual)6.93x
EPS Basic Excl Extra (Annual)$0.15
P/FCF (TTM)4.62x
Receivables Turnover (TTM)4.97x
EV / Free Cash Flow (TTM)8.48x
Total Debt / Equity (Quarterly)0.56x
EPS Incl Extra (TTM)$0.58
Receivables Turnover (Annual)4.60x
ROI (TTM)17.90%
P/S Ratio (TTM)1.63x
Pretax Margin (5Y Avg)-12.39%
Revenue / Share (Annual)$1.82
Tangible BV / Share (Annual)$4.24
Forward P/E3.06x
Free OCF CAGR (5Y)-5.33%
Price vs S&P 500 (52W)438.46%
P/E Ratio (TTM)5.75x
EPS Growth TTM (YoY)2150.00%
Year-to-Date Return5.93%
5-Day Price Return-8.93%
EPS Normalized (Annual)$0.15
ROA (5Y Avg)-28.73%
Net Profit Margin (Annual)8.11%
Month-to-Date Return-13.56%
Cash Flow / Share (TTM)$-5.48
EBITD / Share (Annual)$0.62
EPS Growth (3Y)-46.07%
Operating Margin (Annual)33.26%
LT Debt / Equity (Annual)0.61x
P/CF (TTM)5.24x
ROI (5Y Avg)8.20%
P/E Excl Extra (TTM)5.75x
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$0.58
P/B Ratio (Annual)2.91x
Inventory Turnover (TTM)16.12x
Pretax Margin (TTM)47.43%
Book Value / Share (Annual)$4.24
Price vs S&P 500 (13W)-12.21%
Net Margin Growth (5Y)-21.54%
Beta0.24x
P/FCF (Annual)4.63x
Revenue / Share (TTM)$2.17
ROE (TTM)29.31%
52-Week Low$0.56
vGradeA
gGradeC
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.24est. 0.24
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.90
3.90
3.90
3.90
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IRWDIronwood Pharmaceuticals, Inc. - Class A | A | C | B | $3.46 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. The company markets LINZESS and CONSTELLA (both linaclotide) for the treatment of irritable bowel syndrome with constipation, chronic constipation, and functional constipation across North America, Europe, and Asia-Pacific regions.